Terminated PHASE4 INTERVENTIONAL 2-arm NCT00537732

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing (GERD)

Sponsor: Matthias Schwab

Interventions omeprazole

Updated 6 times since 2017 Last updated: Feb 24, 2014 Started: Apr 30, 2007 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

recruitment problems

Other terminated trials from Matthias Schwab

Drug Metabolism, Poor, CYP2D6-RELATED · Phase PHASE1 · Jun 2015

More terminations from Matthias Schwab

Other Gastroesophageal Reflux trials with similar outcome

Browse all Gastroesophageal Reflux trials

This PHASE4 trial investigates Gastroesophageal Reflux and is currently terminated or withdrawn. Matthias Schwab leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Aug 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Matthias Schwab

Data source: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stuttgart, Germany